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AIDS-associated Non-Hodgkin's lymphoma (AIDS-NHL)
remains a problem even in the era of effective anti-retrovi-
ral therapy. Recent studies have suggested that the chem-
okine, CXCL13, and its receptor, CXCR5 may play a role
in B cell tumors (non-AIDS-associated). Normally,
CXCL13 is expressed in secondary lymphoid tissues and
directs the homeostatic movement of CXCR5(+) B cells
through these areas.
To evaluate the role that CXCL13 and CXCR5 might play
in AIDS-NHL, serum of individuals (n = 46) who ulti-
mately developed AIDS-NHL was obtained from the Mul-
ticenter AIDS Cohort Study (MACS) at UCLA. The AIDS-
NHL serum specimens tested were collected at a mean of
8.9 months prior to NHL diagnosis (SD = 7.9 months).
Sera from AIDS (non-lymphoma), healthy HIV-positive,
and HIV-negative control subjects were also included in
the study. The mean CXCL13 level in the AIDS-NHL
group (158 pg/ml, SD = 153) was ~50 percent higher than
the AIDS control group (98.4 pg/ml, SD = 70.9, P = 0.02).
Furthermore, CXCL13 levels correlated with sCD44 levels
in the AIDS-NHL group (R = 0.31, P = 0.04), but not in the
AIDS control group (R = 0.07; P = 0.7, data not shown);
we previously showed that sCD44 levels are elevated prior
to AIDS-NHL development. CXCL13 levels in the AIDS-
NHL group were also ~2.5 times greater than levels in the
HIV-positive group, and ~7 times greater than levels in the
HIV-negative group (P < 0.001 for both comparisons).
Next, tissue arrays were obtained from the AIDS & Cancer
Specimen Resource (ACSR) that contained numerous sec-
tions of primary AIDS-NHLs, including both the Burkitt
and diffuse large cell subtypes. By immunohistochemis-
try, all primary AIDS-NHLs (24/24) expressed CXCR5,
and 22/24 of the AIDS-NHL specimens also showed
expression of CXCL13. Cell lines derived from primary
AIDS-NHL tumors also showed strong expression of
CXCR5, and occasionally, low levels of expression of
CXCL13. AIDS-NHL cell lines also demonstrated chemo-
taxis towards CXCL13.
These results indicate that CXCL13 and CXCR5 may play
a role in the biology of AIDS-NHL, possibly by affecting
the movement of pre-malignant and/or malignant B cells.
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